Products
Bezetabart Biosimilar Antibody-Drug Conjugate (CD74) for Research
Cat No.: GMP-Bios-INN-1104
Anti-CD74/HLA class II histocompatibility antigen gamma chain therapeutic antibody (Pre-made Bezetabart biosimilar,Whole mAb ADC) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Bezetabart (development codes STRO-001/BN301) is an antibody-drug conjugate targeting CD74. It is developed by Sutro Biopharma and BioNova Pharmaceuticals for B-cell malignancies. It is in Phase I/II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1104-1mg | 1mg | 4635 |
| GMP-Bios-INN-1104-10mg | 10mg | |
| GMP-Bios-INN-1104-100mg | 100mg | |
| GMP-Bios-INN-1104-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Bezetabart biosimilar, Whole mAb ADC, Anti-CD74/HLA class II histocompatibility antigen gamma chain Antibody: Anti-CD74/HLA class II histocompatibility antigen gamma chain/HLA-DR antigens-associated invariant chain/Ia antigen-associated invariant chain (Ii) therapeutic antibody |
| INN Name | Bezetabart |
| Target | CD74/HLA class II histocompatibility antigen gamma chain |
| Format | Whole mAb ADC |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2023 |
| Year Recommended | 2024 |
| Companies | Sutro Biopharma;BioNova Pharmaceuticals;Sutro Biopharma |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Diffuse large B cell lymphoma;Follicular lymphoma;Mantle-cell lymphoma;Non-Hodgkin's lymphoma;Acute myeloid leukaemia;Haematological malignancies;Multiple myeloma;Leukaemia |
| Production | na |
| Development Tech | Modified at two specific positions with reactive 4-(azidomethyl)-L-phenylalanine residues |
